Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

The Roskamp Institute is currently determining whether beta-amyloid, a protein, is useful in the screening of individuals who are at risk of developing Alzheimer’s Disease and monitoring how current sufferers are responding to treatments. Scientists at the Institute have published their scientific findings that indicate that beta-amyloid could serve as an important biomarker for the disease in the “The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels” article for the journal Neuroscience Letters.

Visit Roskamp Institute’s press release about these developments for more information.